Welcome to SAGE Therapeutics first quarter 2025 financial results conference call. (Operator Instructions). This call is being webcast live on the investors and media section of Sage's website at ...

SAGE's earnings and revenues miss estimates in the first quarter of 2025. The company focuses on the commercialization of its depression drug Zurzuvae.

A total of 4 analyst ratings have been received for Sage Therapeutics, with the consensus rating being Neutral. The average one-year price target stands at $9.5, suggesting a potential 21.95% upside.

Sage Therapeutics reported strong Q1 2025 growth, with ZURZUVAE leading the charge in postpartum depression treatment.

Sage Therapeutics Inc (SAGE) reports significant growth in ZURZUVAE prescriptions and collaboration revenue, alongside a ...

Good afternoon. Welcome to Sage Therapeutics First Quarter 2025 Financial Results Conference Call. [Operator Instructions] This call is being webcast live on the Investors and Media section of ...

Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compares to loss of $1.80 per share a year ago.

Sage Therapeutics reported a net loss of $62.2 million for Q1 2025, with an earnings per share (EPS) of -1.01, slightly missing the forecast of -0.99. Revenue reached $14.06 million, falling short ...

Sage Therapeutics, Inc. SAGE reported a loss of $1.01 per share for the first quarter of 2025, wider than the Zacks Consensus Estimate of a loss of 99 cents. The company had reported a loss of $1. ...